Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme

Sexually Transmitted Infections

Volumn 87, Issue 1, 2011, Pages 52-57

  Oteng, Bridgette ^a   Marra, Fawziah ^a,b   Lynd, Larry D ^a,c   Ogilvie, Gina ^a,b   Patrick, David ^a,b   Marra, Carlo A ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CONDYLOMA ACUMINATUM; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PRIORITY JOURNAL; SCREENING TEST; STRUCTURED QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION;

ADOLESCENT; CANADA; CONDYLOMATA ACUMINATA; COST OF ILLNESS; FEMALE; FINANCING, PERSONAL; HUMANS; MALE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; PUBLIC OPINION; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS;

EID: 78751642824     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.2009.041392     Document Type: Article

References (34)

1. National Cancer Institute of Canada. Canadian cancer statistics 1997. Toronto: National Cancer Institute of Canada, 1997.
2. Health Canada. Screening for cervical cancer. http://www.hc-sc.gc.ca/iyh- vsv/diseases-maladies/cervical-uterus-e.html (accessed 11 Jun 2007).
3. Public Health Agency of Canada. Cancer surveillance on-line. http://dsol-smed.phac-aspc.gc.ca/dsol-smed/cancer/c-time-e.html (accessed 11 Jun 2007).
4. Public Health Agency of Canada. Cervical cancer screening in Canada: 1998 surveillance report. http://www.phac-aspc.gc.ca/publicat/ccsic-dccuac/index. html (accessed 11 Jun 2007).
5. Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. JAMA 1994;7:530-4.
6. Olesen A. case-control study of cervical cytology before diagnosis of cervical cancer in Denmark. Int J Epidemiol 1988;17:501-8.
7. Maxwell CJ, Bancej CM, Snider J, et al. Factors important in promoting cervical cancer screening among Canadian women: Findings from the 1996-97 National Population Health Survey (NPHS). Can J Public Health 2001;92:127-33.
8. Miller AB. Editorial: failures of cervical cancer screening. Am J Public Health 1995;85:761-2.
9. Healey SM, Aronson KJ, Mao Y, et al. Oncogenic human papillomavirus infection and cervical lesions in Aboriginal women of Nunavut, Canada. Sex Transm Dis 2001;28:694-700.
10. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
11. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005;191:182-92.
12. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-8.
13. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95:46-52.
14. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.[comment]. J Pathol 1999;189:12-19.
15. National Advisory Committee on Immunization (NACI). Statement on human papillomavirus vaccine. CCDR 2007;33(ACS-2):1-32.
16. Merck Frosst Canada Ltd. Gardasil [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] product monograph. Merck Frosst Canada Ltd, 2006.
17. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
18. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
19. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369(9574):1693-702.
20. Brazier J, Radcliffe J, Salomon JA, et al. Measuring and valuing health benefit for economic evaluation. Oxford, UK: Oxford University Press, 2007.
21. Ryan M, Bate A, Eastmond CJ, et al. Use of discrete choice experiments to elicit preferences. Qual Health Care 2001;10(Suppl 1)i55-60.
22. Ogilvie GS, Remple VP, Marra F, et al. Parental intention to have daughter receive the human papillomavirus vaccine. CMAJ 2007;177:1506-12. (Pubitemid 350248162)
23. Train K. Mixed logit estimation by maximum simulated likelihood. http://elsa.berkeley.edu/Software/abstracts/train1006mxlmsl.html (accessed 4 Sep 2009).
24. Hall J, Kenny P, King M, et al. Using stated preference discrete choice modeling to evaluate the introduction of varicella vaccination. Health Econ 2002;11:457-65.
25. McTaggart-Cowen HM, Shi P, FitzGerald JM, et al. An evaluation of patients' willingness to trade symptom-free day for asthma-related treatment risks: a discrete choice experiment. J Asthma 2008;45:630-8.
26. Olshen E, Woods ER, Austin SB, et al. Parental acceptance of the human papillomavirus vaccine. J Adolescent Health 2005;37:248-51. (Pubitemid 41139956)
27. Lenselink CH, Gerrits MM, Melchers WJ, et al. Parental acceptance of the Human Papillomavirus vaccines. EJOG 2008;137:103-7.
28. Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge, UK: Cambridge University Press, 2005.
29. Brabin L, Roberts SA, Farzaneh F, et al. Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccines 2006;24:3087-94.
30. Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009;27:913.
31. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007;97:1322-8. (Pubitemid 350035812)
32. Newall AT, Beutal P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet 2007;7:289-96.
33. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28-41.
34. Taylor AM, Cahn-Weiner DA, Garcia PA. Examination of volunteer bias in research involving patients with psychogenic nonepileptic seizures. Epilepsy Behav 2009;15:524-6.